Original contributionConcordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas☆
References (48)
p53 Immunohistochemistry: A word of caution
Hum Pathol
(1994)- et al.
Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma
Lancet
(1992) - et al.
Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer
Gastroenterology
(1993) - et al.
Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival
Hum Pathol
(1994) - et al.
Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations
Hum Pathol
(1994) p53: Guardian of the genome
Nature
(1992)- et al.
p53 In tumor pathology: Can we trust immunohistochemistry?—revisited
J Pathol
(1994) - et al.
High levels of p53 protein in UV irradiated normal human skin
Oncogene
(1993) p53 In tumor pathology: Can we trust immunohistochemistry?
J Pathol
(1992)- et al.
Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas
Br J Cancer
(1994)
The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival
Int J Cancer
Cytoplasmic accumulation of p53 protein: An independent prognostic indicator in colorectal adenocarcinomas
J Natl Cancer Inst
Two distinct mechanisms alter p53 in breast cancer: Mutation and nuclear exclusion
Immunohistochemical analysis of p53 in gynecological tumors
Am J Clin Pathol
p53 Gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma
Am J Pathol
p53 Expression in colorectal tumors
Am J Pathol
p53 Mutations and histological type of invasive breast carcinoma
Cancer Res
Accumulation of p53 protein as an indicator for p53 gene mutation in breast cancer
Diagn Molec Pathol
Prognostic significance of TP53 alterations in breast carcinoma
Br J Cancer
Correlation between p53 mutations and antibody staining in breast carcinoma
Br J Surg
p53 Immunohistochemical analysis in breast cancer with four monoclonal antibodies: Comparison of staining and PCR-SSCP results
Br J Cancer
Overexpression and mutation of p53 in endometrial carcinoma
Cancer Res
Prognostic significance of p53 overexpression in endometrial cancer
Cancer Res
p53 Expression and prognosis in gastric carcinoma
Int J Cancer
Cited by (145)
Carcinoma of Unknown Primary
2014, Abeloff's Clinical Oncology: Fifth EditionContributions of molecular analysis to the diagnosis and treatment of gastrointestinal neoplasms
2013, Seminars in Diagnostic PathologyCitation Excerpt :All of these facts must be kept in mind when evaluating the results of p53 IHC. Numerous studies, largely published in the mid-1990s, have correlated p53 IHC with TP53 mutation status.6,8–11 Bass et al.6 performed an evaluation of 6 commercially available p53 antibodies in 19 TP53 genetically defined colorectal neoplasms.
Cytoplasmic sequestration of the tumor suppressor p53 by a heat shock protein 70 family member, mortalin, in human colorectal adenocarcinoma cell lines
2012, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Though accumulation of mutated tumor suppressors and oncogenes is the leading cause for cancer development [11], functional p53 protein is also inactivated through several other mechanisms including binding to viral or cellular products [12–14], inefficient nuclear transport [15], and conformation and translational status changes [16,17]. All aberrations can additionally lead to conformational changes of p53 and subsequent stabilization of the protein making it detectable [6], removing its regulatory influence on cell proliferation thus conferring growth advantages [13] and pre-disposing cells to further genetic mutations, including mutations that lead to inactivation of TP53. The mitochondrial heat shock protein mortalin was originally discovered in embryonic mouse fibroblasts, where two forms were isolated, mot-1 and mot-2, differing in two amino acids.
Molecular-assisted immunohistochemical optimization
2010, Acta Histochemica
- ☆
Supported by grants from the Cancer Foundation of Western Australia, the Sir Charles Gairdner Hospital Research Foundation, and the Foundation for Women's and Infant's Health, King Edward Memorial Hospital.